An Overview of Sugammadex

Original article by:

Dr Ciara Mitchell
Anaesthetic Registrar, Royal Victoria Hospital, Belfast, Northern Ireland

Dr Steve Lobaz
Consultant in Anaesthetics and Intensive Care Medicine, Barnsley Hospital NHS Foundation Trust, Barnsley, UK

Edited by:
Dr Emma Giles
Introduction

Sugammadex is a unique reversal agent of aminosteroid-induced neuromuscular blockade. It is the first agent in its class. Initial human trials in 2005 found sugammadex to be safe and effective. Further studies followed, resulting in sugammadex being approved for clinical use in Europe and Australia in 2008. In 2015 the Food and Drug Administration (FDA) agency licensing approval for the USA was finally given.

Sugammadex is a credible alternative to anticholinesterases in anaesthesia, it allows the use of rocuronium as a substitute to suxamethonium for rapid sequence induction (RSI) and has many potential uses in clinical practice, some of which we will discuss in this review.

Mechanism of action

Sugammadex is a direct reversal agent for aminosteroid neuromuscular blocking drugs (NMBD). It is a modified gamma cyclodextrin with a hydrophilic exterior and lipophilic centre, allowing it to encapsulate all aminosteroid NMBDs, with greatest affinity for rocuronium followed by vecuronium and then pancuronium. Each molecule of sugammadex encapsulates one molecule of rocuronium (Figure 1).

Sugammadex works by two mechanisms, firstly on entering the plasma it encapsulates the circulating aminosteroid rendering it inactive. Secondly, it promotes dissociation of the aminosteroid from the neuromuscular junction (NMJ) by creating a concentration gradient from the NMJ to the plasma, where it too is also encapsulated. This encapsulation of the NMBD allows return of neuromuscular function (NMF).

Pharmacokinetics

The pharmacokinetics of sugammadex is linear in the dose range 0.1mg/kg - 32mg/kg. However, one safety and efficacy study has suggested this linear relationship extends up to 96mg/kg. In the healthy adult population sugammadex has an estimated volume of distribution of 11-14 litres, an elimination half-life of around two hours and clearance of 88ml/min. Sugammadex is not metabolized and is excreted almost exclusively unchanged by the kidneys with more than 90% being renally excreted within 24 hours. Interestingly, administration of sugammadex alters the pharmacokinetics of rocuronium with the rocuronium-sugammadex complex behaving in a similar manner to sugammadex, with elimination of rocuronium being shifted away from the biliary system to predominant renal excretion.
Dosing

Due to one-to-one binding capacity with rocuronium, sugammadex has the ability to reverse any depth of rocuronium induced neuromuscular blockade. The dose of sugammadex required to ensure complete reversal is dependent upon the depth of block, the timing and dose of rocuronium. The terminology used for depth of block: routine, moderate and profound, is defined by response to neuromuscular monitoring, train-of-four (TOF) and post-tetanic count (PTC). Routine block is represented by a TOF of 2 or more. Moderate block represents a deeper level of block and corresponds to a TOF of 0 and PTC 1-2. Profound block is the deepest level of neuromuscular block and occurs 3-5 minutes post NMBDs when there is no response on neuromuscular monitoring to TOF or PTC. Adequate reversal is determined by a TOF of >0.9, were the height of the forth twitch is 90% of the height of the first twitch.

<table>
<thead>
<tr>
<th>Type of Block</th>
<th>Dose of Sugammadex</th>
<th>Time to TOF &gt;0.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine – TOF count 2</td>
<td>2mg/kg</td>
<td>2 minutes</td>
</tr>
<tr>
<td>Moderate – Post tetanic count 1-2</td>
<td>4mg/kg</td>
<td>3 minutes</td>
</tr>
<tr>
<td>Profound – 3-5 minutes post NMBDs</td>
<td>16mg/kg</td>
<td>1.5 minutes</td>
</tr>
</tbody>
</table>

Figure 2: Table showing dose of sugammadex required to reverse different levels of rocuronium neuromuscular blockade.

For reversal of routine and moderate rocuronium and also vecuronium-induced blockade, similar doses of sugammadex are required. However, the dose of sugammadex for reversal of profound vecuronium induced block has not been studied and therefore has not been formally determined.

It is important to note that there is great variability in recovery times after administration of sugammadex at all depths of block and therefore neuromuscular monitoring is recommended until complete reversal is clinically achieved.

Reduced doses of sugammadex (<2mg/kg) is associated with prolonged recovery times and incomplete reversal and is therefore not recommended.

Should the situation arise that the patient requires repeat neuromuscular blockade after having received a dose of sugammadex, the recommendation is to utilise an alternative NMBD, for example, suxamethonium or a benzylisoquinolinium in the first instance. However, it is sometimes possible to re-paralyse the patient with rocuronium, but the dose required depends on the sugammadex dose given and the time since administration (Table Two). Paralysis onset with rocuronium in this situation is often delayed, with duration of action being shorter than normal.

<table>
<thead>
<tr>
<th>Time since 4mg/kg sugammadex administration</th>
<th>Dose of NMBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 minutes</td>
<td>1.2mg/kg rocuronium</td>
</tr>
<tr>
<td>4 hours</td>
<td>0.6mg/kg rocuronium or 0.1mg/kg vecuronium</td>
</tr>
</tbody>
</table>

Figure 3: Table showing the dose of rocuronium required after administration of sugammadex.
Implications for practice

Sugammadex versus Neostigmine

Following the administration of a non-depolarising NMBD, reversal often occurs spontaneously over a set duration of time or can in most cases be expedited through the administration of an anticholinesterase such as neostigmine in combination with glycopyrrolate. Neostigmine has well recognised undesirable effects and can result in variable reversal of neuromuscular blockade. It also has the disadvantage of not being able to reverse profound depth of blockade. If given during profound or moderate level of neuromuscular blockade, neostigmine can potentially exacerbate neuromuscular block by direct action on open nicotinic receptors. Early studies established that sugammadex compared with neostigmine was superior in producing complete reversal of neuromuscular blockade from both routine and moderate levels of block, occurring up to 17 times faster with sugammadex. These results have been consistent in subsequent studies, along with recognition of a reduced risk of post-operative residual blockade with sugammadex compared to neostigmine. A recent systematic review looked at the clinical benefit of sugammadex versus neostigmine in reducing events associated with post-operative residual blockade. This review found no difference in the occurrence of nausea and vomiting or any major life-threatening post-operative event when comparing sugammadex and neostigmine use.

Another postulated benefit of sugammadex is facilitation of a moderate to profound neuromuscular blockade to the end of surgery, to improve surgical operating conditions and in theory outcomes. Determining clinical benefit of this technique is difficult as discussed in a recent review of laparoscopic surgery. Optimisation of operating conditions is not solely dependent on depth of block but also factors such as anaesthetic technique and laparoscopic inflation pressures. Most operating surgeons are often unable to ascertain differences between depths of blockade clinically.

Sugammadex / rocuronium versus Suxamethonium

Suxamethonium has been the muscle relaxant of choice in rapid sequence induction (RSI) due to its rapid onset and offset of action. However, it is associated with numerous and potentially life-threatening adverse effects. Rocuronium 1.2mg/kg can emulate the intubating conditions of suxamethonium for RSI, but with the consequence of a prolonged duration of action, 35-75 minutes compared with less than 10 minutes. Administration of sugammadex after high dose rocuronium 1.2mg/kg, profound blockade, can result in a quicker return of NMF when compared to spontaneous resolution of suxamethonium induced blockade. Sugammadex at a dose of 16mg/kg will reverse profound neuromuscular blockade within 1.3 to 1.9 minutes post administration. However, time taken to locate, calculate the dose and administer sugammadex may significantly delay time to reversal. It must be recognised that return of NMF does not necessarily equate to return of spontaneous ventilation in a ‘can’t intubate, can’t ventilate’ (CICV) situation. However, there are some case reports of successful use of sugammadex in CICV situations, warranting its inclusion on a departmental difficult airway trolley.

Compared with suxamethonium, the use of rocuronium and sugammadex to facilitate electroconvulsive therapy (ECT) has been associated with shorter recovery times and reduced post-operative complaints such as myalgia and headache.

Sugammadex for the treatment of rocuronium-induced anaphylaxis

It has been postulated that sugammadex has a role to play in the treatment of rocuronium-induced anaphylaxis, leading to a number of case reports. Such findings have not been supported by cutaneous testing or in-vitro experiments. A recent case-controlled study analysing sugammadex in the management of presumed rocuronium-induced anaphylaxis also could not endorse sugammadex use in this setting.
Specific populations

Elderly
The recommended dose of sugammadex for the elderly (>75yrs) is the same as younger adult patients. However, onset of action may be slower, which is possibly attributed to a reduced cardiac output in the elderly population.

Paediatrics
Routine reversal of TOF count 2 with sugammadex 2mg/kg in children age two to 17 is recommended. However, despite safe use in a small number of case reports, sugammadex use is not endorsed in neonates or infants.

Pregnancy and breastfeeding
There are no documented cases of sugammadex being used during pregnancy and is not recommended despite minimal placental transfer. There is however, multiple case reports of administration to women post caesarean section, which may allow rocuronium to become an acceptable alternative NMBD to suxamethonium for emergency obstetric intubation.

Obesity
There is an ongoing debate surrounding the dosing of sugammadex in obese patients, as currently dosing is based on actual body weight. However, dose based on ideal body weight (IBW) plus 40% appears to be safe. Dosing based on IBW alone has been associated with slower recovery times and may lead to an increased risk of inadequate reversal.

Specific considerations

Neurological disease
Patients with myasthenia gravis pose particular challenges regarding NMBDs, as they require reduced doses, which have a variable duration of action, increasing the risk of post-operative residual blockade. Cholinesterase inhibitors such as neostigmine can result in inadequate reversal of NMBDs especially in patients who are taking pyridostigmine. A case series of 21 patients demonstrated that sugammadex was a safe and an effective alternative to neostigmine in patients with myasthenia gravis. De Boer et al also showed recovery times were similar to patients without neuromuscular diseases for reversal of both routine and moderate block to a TOF>0.9.

There are case reports of safe sugammadex use in other neurological conditions including myotonic dystrophy, amyotrophic lateral sclerosis, Duchenne Muscular Dystrophy and Huntington’s disease.

Cardiorespiratory disease
Sugammadex is safe for use in patients with pulmonary diseases such as bronchiectasis and cystic fibrosis. Bronchospasm has been documented following administration in a small number of patients. Sugammadex has also been used effectively in patients with cardiac failure and those who have received a heart transplant, but with a prolonged recovery time compared to the adult population. It is postulated again that this delayed recovery is due to reduced cardiac output as with the elderly population.

Renal disease
Sugammadex use in patients with a creatinine clearance <30ml/min is not recommended. However a recent safety and efficacy study comparing reversal of moderate block with sugammadex 4mg/kg in patients with creatinine clearance <30ml/min to those with >80ml/min demonstrated complete reversal in those with severe renal impairment. Sugammadex was significantly slower at achieving a TOF>0.9 in the renally impaired compared to the normal population group, 3.1 versus 1.9 minutes. Sugammadex-rocuronium clearance was significantly reduced and remained detectable in a number of subjects seven days post administration. Using a high flux filter, haemodialysis can be used to remove sugammadex.

Liver disease
Evidence for the use of sugammadex in liver dysfunction is limited. However, as sugammadex is almost solely excreted renally, no dose reduction is necessary in patients with mild to moderate hepatic dysfunction. More studies are needed in this area.
Drug interactions

Co-administration of sugammadex is not recommended with ondansetron, verapamil and ranitidine due to physical incompatibility. The effect of sugammadex is not altered by administration of magnesium and appears to be equally effective with both volatile and intravenous anaesthesia. The main drug interactions associated with sugammadex are displacement and capture reactions. Displacement reaction occurs when a drug displaces rocuronium from its sugammadex-rocuronium complex causing a theoretical risk of recurisation. Potential drugs causing displacement include toremifene, fusidic acid, flucloxacillin and diclofenac. However, such reactions have not been correlated into clinical practice. It should also be noted that rocuronium-sugammadex has an extremely high association constant and very low dissociation constant. Capturing reactions reduce the efficacy of other drugs when sugammadex encapsulates them. The most significant risk is with hormonal contraceptives, which may be less effective. Any woman who has received sugammadex should be counselled accordingly. They should obey the seven-day contraceptive rule and use extra contraceptive precautions for seven days following administration of sugammadex.

Adverse effects

Hypersensitivity although rare, is by far the most concerning adverse effect of sugammadex, with a literature review highlighting that this can be severe and rapid in nature (anaphylaxis), with most cases presenting within five minutes of sugammadex exposure. It is important to note that none of the patients in the literature review died. It is not clear why sugammadex exposure may result in hypersensitivity, but previous food and pharmaceutical cyclodextrin exposure may be to blame. The incidence of hypersensitivity reactions is estimated at <1% after a single dose and is likely to increase with higher and repeated dosing of sugammadex. Diagnosis is confirmed via intradermal skin prick testing.

Despite this, sugammadex is generally well tolerated. Common side effects include dysgeusia, headache, fatigue, nausea, vomiting, dizziness, urticaria and abdominal pain. An issue noted in initial studies was symptoms of inadequate depth of anaesthesia post administration of sugammadex such as grimacing, sucking and coughing. Elevated bispectral index levels were also noted post sugammadex administration. The FDA raised concerns regarding QTc prolongation, however subsequent studies using doses of sugammadex up to 32mg/kg have demonstrated there is no difference in QTc compared with placebo. A further issue highlighted by the FDA was the effect of sugammadex on coagulation due to early studies suggesting an increase in activated partial thromboplastin time (aPTT) possibly by the transient inhibition of factor Xa. A transient increase in aPTT and prothrombin time (PT) at 10 minutes that normalises by one hour in doses of 4mg/kg have not been associated with adverse clinical consequences. These results have been mirrored in other studies with sugammadex 4mg/kg, however further studies are needed with higher doses of sugammadex.

Animal studies have suggested that sugammadex may be neurotoxic, but also highlighted that penetration of sugammadex across the blood-brain barrier is minimal, reducing this potential risk in humans.

Cost implications

In the UK, sugammadex costs £29.82 per millilitre (100mg/ml). This compares with £1.15 per millilitre of neostigmine (2.5mg combined with 500 micrograms of glycopyrronium bromide). Unrestricted access to sugammadex has been associated with increased financial cost in a number of studies, without necessarily increasing patient turnover. Failure to use sugammadex in an emergency has also been cited as a potential medicolegal issue. Increased use of rocuronium may be associated with its own consequences such as increased rates of anaphylaxis.
Summary

Sugammadex is an effective and safe agent for reversing aminosteroid neuromuscular blockade, in particular all depths of rocuronium-induced blockade. Sugammadex provides a real alternative to neostigmine and has been used successfully in many clinical areas and patient populations that would have previously posed great angst to the anaesthetist, including patients with neuromuscular disorders. Sugammadex use has allowed rocuronium to become a comparable alternative to suxamethonium for RSI. Despite these virtues and being generally well tolerated globally, there are still some concerns regarding hypersensitivity, particularly by the FDA in the United States.

Experience with sugammadex worldwide is increasing, with many countries approving and using sugammadex safely. However, at present, routine first-line use of sugammadex has not been shown to be cost-effective. Further research is needed to improve how sugammadex use could be tailored to improve specific situations and become more financially viable. The safety of sugammadex in terms of hypersensitivity reactions and safety in certain populations such as paediatrics and pregnancy needs to be fully determined.

References and Further Reading


This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/)

Copyright remains with the original authors.

Original article found at: [http://www.wfsahq.org/resources/anaesthesia-tutorial-of-the-week](http://www.wfsahq.org/resources/anaesthesia-tutorial-of-the-week)